NEW YORK, July 24, 2017 /PRNewswire/ --
If you want a Stock Review on EXEL, CLDX, CLVS, or GERN then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. This morning's focus is on the Biotech space, which is one of the hardest sectors to invest in. It is for the robust investor, who seeks high risk/reward on
South San Francisco, California headquartered Exelixis Inc.'s stock finished last Friday's session 0.89% higher at $27.23. A total volume of 2.19 million shares was traded. The Company's shares have advanced 13.36% in the past month, 29.79% over the previous three months, and 82.63% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 22.55% and 42.32%, respectively. Additionally, shares of Exelixis, which engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer, have a Relative Strength Index (RSI) of 73.66.
On July 14th, 2017, research firm SunTrust initiated a 'Buy' rating on the Company's stock, with a target price of $33 per share.
On July 17th, 2017, Exelixis announced that its Q2 2017 financial results will be released on August 02nd, 2017, after the markets close. At 5:00 p.m. EDT on that same day, management will host a conference call to discuss the results and provide a general business update. The conference call will be accessible under the Investors & Media page of the Company's website. Visit us today and access your complete report on EXEL for free at:
On Friday, shares in Hampton, New Jersey headquartered Celldex Therapeutics Inc. ended the session 0.84% lower at $2.36. The stock recorded a trading volume of 952,289 shares. The Company's shares are trading 11.22% below their 50-day moving average. Moreover, shares of Celldex Therapeutics, which focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics, have an RSI of 36.12. The complimentary research report on CLDX can be accessed at:
Boulder, Colorado headquartered Clovis Oncology Inc.'s shares gained 1.61%, closing the session at $86.64 with a total trading volume of 1.14 million shares. The stock has surged 59.29% over the previous three months and 95.05% on an YTD basis. The stock is trading 20.43% and 57.63% above their 50-day and 200-day moving averages, respectively. Additionally, shares of Clovis Oncology, which focuses on acquiring, developing, and commercializing anti-cancer agents in the US, Europe, and internationally, have an RSI of 53.35.
On July 07th, 2017, research firm Gabelli & Co initiated a 'Buy' rating on the Company's stock, with a target price of $125 per share. Register for free on DailyStockTracker.com and download the research report on CLVS at:
Last Friday at the close, shares in Menlo Park, California-based Geron Corp. recorded a trading volume of 804,971 shares. The stock ended the session 0.36% lower at $2.80. The Company's shares have advanced 17.65% over the previous three months and 35.27% since the start of this year. The stock is trading above its 200-day moving average by 19.85%. Furthermore, shares of Geron, which operates as a biopharmaceutical company, have an RSI of 43.73. Get free access to your research report on GERN at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207) 331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Learn the basics about diabetes and how to bring it under control with turmeric, an highly ...
Antioxidants are artificial or natural components that help protect the human body from the damage ...
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...View All